Predict your next investment

Eutropics company logo
HEALTHCARE | Drug Discovery
eutropics.com

See what CB Insights has to offer

Stage

Debt | Alive

Total Raised

$8.94M

Last Raised

$350K | 19 days ago

About Eutropics

Eutropics is a biomarker discovery and clinical diagnostics laboratory that develops functional clinical diagnostic tests that recognize unique features of cancer cells from individual patients.

Eutropics Headquarter Location

767-C Concord Avenue

Cambridge, Massachusetts, 02138,

United States

617-714-4405

Latest Eutropics News

Eutropics' PraediCare Dx™ Noxa Biomarker Driven Clinical Study Data Presented at the 23rd Annual Congress of the European Hematology Association (EHA)

Jun 19, 2018

Share this article CAMBRIDGE, Mass., June 19, 2018 /PRNewswire/ -- At last week's EHA meeting, Tolero Pharmaceuticals, Inc. presented positive data in patients treated with alvocidib, a cyclin-dependent kinase (CDK) inhibitor class drug, in combination with standard of care for acute myeloid leukemia: Zeidner, et al., "Phase II Study Incorporating a Novel BH3-Profiling Biomarker Approach of Alvocidib Followed by Cytarabine and Mitoxantrone in Relapsed/Refractory Acute Myeloid Leukemia (AML)," EHA23, Abstract PF243. The trial design relied on selecting patients using a novel functional biomarker. Eutropics' PraediCare Dx™ Noxa test provided the patient sample readout that revealed dependence on the anti-apoptotic protein MCL1. The data from the trial indicates that a majority of patients selected using Eutropics' PraediCare Dx™ Noxa test achieved complete remission. Encouraged by the improved response rates in selected patients Tolero announced that they will continue their Phase 2 study on alvocidib in patients with relapsed and refractory, MCL1-dependent AML. PraediCare Dx™ accurately measures this dependence of malignant cells in a unique way that identifies what is termed the "Noxa primed state." Recent studies have shown that in addition to identifying alvocidib responsiveness, the occurrence of the Noxa primed state identifies patients who are most likely to respond to a range of MCL1 perturbing cancer therapies. This important biomarker is being further assessed for use in guiding such cancer treatments. "We believe that the correlation between the PraediCare Dx™-measured drug target function and clinical response to treatment can greatly benefit AML patients, both by speeding clinical development of alvocidib and other drugs in this class and by directing the most efficacious use of these drugs after they are approved," said Michael Cardone, Ph.D., CEO of Eutropics. About PraediCare Dx™ Based on the fundamental principles of apoptosis biology and derived from the BH3 profiling methodology, PraediCare Dx™ provides uniquely accurate predictive functional biomarkers for AML, multiple myeloma and CLL. The PraediCare Dx™ Noxa assay was developed for CDK inhibitor class drugs and for other MCL1 targeting therapies. The platform has applicability to other targeted therapies, including BH3 mimetics. About Eutropics Eutropics is a clinical diagnostics company developing a novel approach for guiding cancer treatment, enabling the delivery of personalized medicines to patients. Eutropics' PraediCare Dx™ platform technology delivers medically useful in vitro diagnostics accelerating drug development including Eutropics' compounds. Contact: Anne Assm

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Eutropics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eutropics is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Eutropics Patents

Eutropics has filed 22 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Oncology
  • Acid fast bacilli
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/12/2016

10/6/2020

Transcription factors, Proteins, Experimental cancer drugs, Oncology, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/12/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/6/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Proteins, Experimental cancer drugs, Oncology, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.